Monday, April 29, 2019

Gilead Sciences Inc's experimental drug aimed at treating a type of fatty liver disease known as NASH failed to meet the main goal of a late-stage study on Thursday, two months after it failed another trial.


from Reuters: Health News https://reut.rs/2PCnbA5

Related Posts:

  • LATEST HEALTH NEWSShares of Australia's biggest listed aged care providers fell on Friday after a government-backed inquiry strongly criticized care of the elderly and vulnerable, raising expectations of a far-reaching regulatory overhaul. … Read More
  • LATEST HEALTH NEWSTeenagers worldwide are jeopardizing their health by failing to get enough exercise to reduce their risk of obesity and cardiovascular diseases, a World Health Organization-led study released on Friday warns. from Reuter… Read More
  • LATEST HEALTH NEWSTBILISI - City dwellers tend to live longer if they are in leafy neighborhoods, according to a study published on Wednesday that linked green areas to lower rates of premature death. from Reuters: Health News https://ift… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Almost 1 in 18 women and 1 in 40 men have experienced sexual harassment in and related to the workplace, according to a U.S. study. from Reuters: Health News https://ift.tt/3669S2g … Read More
  • LATEST HEALTH NEWSFour large drug companies could resume talks on Tuesday to try to reach a $48 billion settlement of all opioid litigation against them, after agreeing with two Ohio counties to a $260 million deal to avert the first federal t… Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner